The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck; Roche
Consulting or Advisory Role - AstraZeneca; BMS/Ono; IMBdx; Janssen; Lilly; Merck; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Lunit; Merck
Travel, Accommodations, Expenses - Novartis
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Ji-Youn Han
Stock and Other Ownership Interests - Yuhan
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - ABION; Bristol-Myers Squibb; J Ints Bio; Janssen; Lantern Pharma; Merck; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Eun Kyung Cho
No Relationships to Disclose
 
Jong-Seok Lee
Consulting or Advisory Role - Yuhan
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
Research Funding - Merck
 
Joshua C Curtin
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Grace Gao
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
John Xie
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Robert W. Schnepp
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Joshua Michael Bauml
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Roland E. Knoblauch
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Johnson & Johnson
 
Meena Thayu
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); inno.N (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)